Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of California, Irvine
About this trial
This is an observational pilot study to examine the association between a patient's personality and adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Eligibility criteria
Qualifiers
18 years of age or older
Diagnosed with chronic myeloid leukemia (CML) and in the chronic phase (CML-CP)
Currently being treated with one of four cancer medications - imatinib, dasatinib, bosutinib, or nilotinib
A patient at the UCI Chao Family Comprehensive Cancer Center (CFCCC), or
Disqualifiers
Unable to read and speak English
Impaired decisional capacity to consent
Trial design
Treatments tested in this trial
- Interview
Treatment groups
75 Participants
are divided into 1 treatment groupLocations
1Chao Family Comprehensive Cancer Center University of California, Irvine92868, OrangeCalifornia, United States
Sponsors and collaborators
University of California, Irvine
Lead sponsor
Source ClinicalTrials.gov